TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27503642
Drug: Ceftazidime-avibactam (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime-avibactam (single 2-h intravenous infusion); cohort 1: 2,000 to 500 mg; cohort 2: 2,000 to 500 mg [≥40 kg] or 50 to 12.5 mg/kg [<40 kg]; cohorts 3 and 4: 50 to 12.5 mg/kg
Study: 27504630
Drug: IgM-enriched immunoglobulin
Normalized name: IgM-enriched immunoglobulins
DrugBank: Pentaglobin (DB15865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgM-enriched immunoglobulin (IgM-IVIg) (5 mg/kg/d over three days)
Study: 27506223
Drug: Smartphone application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone application for insulin titration
Study: 27506432
Drug: Abdominoperineal excision
Normalized name: pNF1-Blast Excised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominoperineal excision (APE) for rectal cancer
Study: 27507113
Drug: Hypochloremia (chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypochloremia (chloride ≤96 mmol/L)
Study: 27507877
Drug: Selinexor (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor (30 mg/m²) in combination with fludarabine and cytarabine
Study: 27510535
Drug: Fish-oil therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil therapy
Study: 27512620
Drug: Ester-C(®) (EC,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ester-C(®) (EC, 1000 mg vitamin C)
Study: 27512620
Drug: Placebo (PL,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL, 0 mg vitamin C)
Study: 27512620
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (AA, 1000 mg vitamin C)
Study: 27514314
Drug: Ultra-hypofractionated radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-hypofractionated radiation treatment
Study: 27514463
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy guided by pharmacogenetic testing
Study: 27514463
Drug: Standard statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard statin therapy without pharmacogenetic guidance
Study: 27515248
Drug: Low-dose humanized
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose humanized anti-CD20 antibody, veltuzumab
Study: 27515250
Drug: Imatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib plus steroids as induction
Study: 27515250
Drug: Imatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib plus chemotherapy during consolidation
Study: 27516088
Drug: Salmeterol/Fluticasone combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/Fluticasone combination (SFC)
Study: 27520989
Drug: ivabradine 5
Normalized name: ivabradine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine 5 mg twice daily (adjusted to 7.5 mg twice daily if HR >60 bpm)
Study: 27521361
Drug: Cessation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cessation of injection drug use
Study: 27521361
Drug: Former injection
Normalized name: Triple Wormer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Former injection drug users who are HCV aviremic
Study: 27525031
Drug: Modified Atkins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Atkins diet (20 to 40 g of carbohydrates daily)
Study: 27525046
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment with extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG (group 2)
Study: 27525190
Drug: T3D-959 (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: T3D-959 (1.0 mg/kg/day)
Study: 27525540
Drug: Exenatide QW
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide QW 2 mg
Study: 27526051
Drug: Conventional medical,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical, laser, or surgical treatment
Study: 27528114
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment course for CRPC patients
Study: 27528724
Drug: AM0010 (Pegylated
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM0010 (Pegylated Recombinant Human Interleukin-10) at doses of 1 to 40 μg/kg once per day, self-administered subcutaneously.
Study: 27530528
Drug: Quarterly postal
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quarterly postal and online antibiotic prescription feedback over 24 months
Study: 27531679
Drug: Daratumumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab plus lenalidomide (25 mg/day orally on days 1-21 of each cycle) and dexamethasone (40 mg/week)
Study: 27532019
Drug: Vemurafenib (VEM)
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib (VEM) 960 mg twice daily for 6 weeks followed by Ipilimumab (IPI) 10 mg/kg every 3 weeks for 4 doses (induction), then every 12 weeks (maintenance) until disease progression or unacceptable toxicity
Study: 27532019
Drug: Vemurafenib (VEM)
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib (VEM) at previously tolerated dose after progression on IPI
Study: 27532363
Drug: HHHFNC at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HHHFNC at 4 to 6 L/min
Study: 27532364
Drug: Exemestane (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane (25 mg oral daily) plus Everolimus (10 mg oral daily)
Study: 27532364
Drug: Exemestane (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane (25 mg oral daily) plus Placebo
Study: 27534260
Drug: Correlation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation with serum insulin concentrations
Study: 27535544
Drug: Daily assessments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily assessments and long-term follow-up
Study: 27535663
Drug: Plerixafor 240
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plerixafor 240 μg/kg administered subcutaneously every other day from day +2 until day +21 or until neutrophil recovery
Study: 27535748
Drug: Evofosfamide (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evofosfamide (120 mg/m2 to 340 mg/m2) administered one week before chemoradiotherapy and repeated weekly up to six doses.
Study: 27535748
Drug: Evofosfamide in
Normalized name: trofosfamide
DrugBank: Trofosfamide (DB12902)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evofosfamide in combination with neo-adjuvant chemoradiotherapy.
Study: 27536421
Drug: Amlodipine/valsartan (A/V)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/valsartan (A/V) 10/160 mg
Study: 27536421
Drug: Losartan/hydrochlorothiazide (L/H)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan/hydrochlorothiazide (L/H) 100/25 mg
Study: 27536422
Drug: Metformin for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin for 52 weeks (active control)
Study: 27536436
Drug: Belimumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belimumab (1 mg/kg and 10 mg/kg)
Study: 27536442
Drug: Migalastat HCl
Normalized name: migalastat HCl
DrugBank: Migalastat (DB05018)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Migalastat HCl 50 mg
Study: 27536442
Drug: Migalastat HCl
Normalized name: migalastat HCl
DrugBank: Migalastat (DB05018)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Migalastat HCl 150 mg
Study: 27536442
Drug: Migalastat HCl
Normalized name: migalastat HCl
DrugBank: Migalastat (DB05018)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Migalastat HCl 450 mg
Study: 27536449
Drug: Levomilnacipran ER
Normalized name: levomilnacipran Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levomilnacipran ER 40-120 mg/day
Study: 27536452
Drug: Levocetirizine oral
Normalized name: levocetirizine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine oral solution (OS) 5 mg
Study: 27536452
Drug: Cetirizine dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine dry syrup (DS) 10 mg
Study: 27536459
Drug: 5 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 × 0.1 mg dutasteride capsules
Study: 27536459
Drug: 1 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 × 0.5 mg dutasteride capsule
Study: 27536708
Drug: Intrathecal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal administration of rituximab
Study: 27537786
Drug: Deferasirox (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox (up to 40 mg/kg/d)
Study: 27538465
Drug: Panagen (tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panagen (tablet form of fragmented human DNA preparation)
Study: 27540019
Drug: High-dose inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose inhaled corticosteroid (ICS) treatment
Study: 27540019
Drug: High-dose ICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ICS
Study: 27544054
Drug: PRAME immunotherapeutic
Normalized name: PrameGel Reformulated Apr 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRAME immunotherapeutic (20 μg)
Study: 27544054
Drug: PRAME immunotherapeutic
Normalized name: PrameGel Reformulated Apr 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRAME immunotherapeutic (100 μg)
Study: 27544054
Drug: PRAME immunotherapeutic
Normalized name: PrameGel Reformulated Apr 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRAME immunotherapeutic (500 μg)
Study: 27544054
Drug: PRAME immunotherapeutic
Normalized name: PrameGel Reformulated Apr 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRAME immunotherapeutic (all doses)
Study: 27547173
Drug: Standard and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard and contingency management treatment
Study: 27547422
Drug: Short-term intensive
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term intensive insulin therapy (IIT) for 2-4 weeks (basal detemir, bolus aspart) followed by placebo therapy for 48 weeks
Study: 27547429
Drug: BQ-123 (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: BQ-123 (selective endothelin A receptor antagonist)
Study: 27550351
Drug: Ceftolozane-tazobactam 3
Normalized name: ceftolozane / tazobactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftolozane-tazobactam 3 g every 8 hours (q8h)
Study: 27551171
Drug: Acetaminophen plus
Normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen plus 10 mg/day of native type II collagen (group AC+CII)
Study: 27551171
Drug: 1500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg/day of acetaminophen (group AC)
Study: 27551317
Drug: Oxidized fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxidized fish oil (8 g daily, EPA+DHA 1.6 g)
Study: 27551317
Drug: High-quality fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-quality fish oil (8 g daily, EPA+DHA 1.6 g)
Study: 27552578
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonist (VKA) treatment in Asia (1356 patients, 37.8%)
Study: 27552578
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonist (VKA) treatment in ORW (7081 patients, 53.3%)
Study: 27554014
Drug: LNG IUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG IUS (levonorgestrel intrauterine system) 52 mg inserted at 2 weeks postpartum
Study: 27554105
Drug: Contemporary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contemporary treatment (pharmacological and invasive)
Study: 27557643
Drug: Selinexor/doxorubicin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor/doxorubicin treatment
Study: 27557949
Drug: Antipsychotic-related dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic-related dopamine D2/3 receptor occupancy
Study: 27558181
Drug: Rifamycin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifamycin treatment
Study: 27558635
Drug: 1 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 × 10^6 CEA-pulsed DCs mixed with tetanus toxoid (adjuvant) and low-dose interleukin-2 administered subcutaneously after final DC vaccination.
Study: 27560141
Drug: Family-based childhood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based childhood obesity treatment program
Study: 27561167
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy in PEGASUS-like population (Group 1)
Study: 27561720
Drug: Clofarabine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofarabine (30 mg/m²) and cytosine arabinoside followed by reduced-intensity conditioning before allogeneic stem-cell transplantation
Study: 27561844
Drug: DEBIRI (drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEBIRI (drug eluting PVA microspheres loaded with irinotecan)
Study: 27561844
Drug: DEBIRI (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEBIRI (median dose of 103 mg irinotecan)
Study: 27565186
Drug: Self-reported medication
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported medication intake and fall incidents via smartphone app
Study: 27566701
Drug: LY3022856 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3022856 at doses of 5-30 mg/kg weekly (qwk)
Study: 27566701
Drug: LY3022856 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3022856 at 30 mg/kg qwk in colorectal cancer patients
Study: 27567500
Drug: Rifampin 20
Normalized name: rifampin 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 20 mg/kg/day
Study: 27567500
Drug: Rifampin 15
Normalized name: rifampin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 15 mg/kg/day
Study: 27567500
Drug: Rifampin 10
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 10 mg/kg/day (control)
Study: 27568453
Drug: Anti-dementia drugs
Normalized name: ANTI-DEMENTIA DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-dementia drugs (acetylcholinesterase inhibitors and memantine)
Study: 27568453
Drug: Control (patients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (patients with dementia who did not take anti-dementia drugs)
Study: 27570087
Drug: Ofatumumab consolidation
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab consolidation (1000 mg once every 4 weeks)
Study: 27570087
Drug: Ofatumumab induction
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab induction (300 mg on day 1 and 1000 mg on day 2; cycles 2-6: 1000 mg on day 1)
Study: 27570245
Drug: Delafloxacin 300
Normalized name: delafloxacin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delafloxacin 300 mg intravenous
Study: 27570807
Drug: IL-6 c.-174
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-6 c.-174 CC genotype
Study: 27572392
Drug: Meropenem 2
Normalized name: meropenem 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 2 g every 8 hours (q8h)
Study: 27572392
Drug: Meropenem 1
Normalized name: meropenem 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 1 g every 8 hours (q8h)
Study: 27572392
Drug: Meropenem 1
Normalized name: meropenem 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 1 g every 6 hours (q6h)
Study: 30730782
Drug: Andexanet alfa
Normalized name: andexanet alfa
DrugBank: Andexanet alfa (DB14562)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Andexanet alfa (bolus followed by a 2-hour infusion)
Study: 27573663
Drug: Vinblastine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinblastine (6 mg/m2) administered once per week
Study: 27575984
Drug: Instrumental Activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instrumental Activities of Daily Living (IADL)
Study: 27576691
Drug: EPI-002 (known
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPI-002 (known AR AF-1 inhibitor)
Study: 27580835
Drug: Drug-eluting stent
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stent implantation
Study: 27581438
Drug: 13-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-valent pneumococcal conjugate vaccine (PCV13), single dose
Study: 27581469
Drug: Pregnancy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnancy with depleted iron stores (SF <12 μg/L)
Study: 27581477
Drug: Maternal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal protein intake during pregnancy (mean second-trimester protein intake: 1.4 g · kg)
Study: 27582220
Drug: Aducanumab (human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aducanumab (human monoclonal antibody) administered via monthly intravenous infusions for one year
Study: 27582480
Drug: Treatment program
Normalized name: ZO Skin Health Acne Prevention Plus Treatment Program KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment program for WTC dust exposure
Study: 27583276
Drug: CoQ10 (2,400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 (2,400 mg/d)
Study: 27583590
Drug: Atazanavir 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir 400 mg once-daily
Study: 27583590
Drug: Higher unboosted
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher unboosted doses or splitting the daily dose to twice-daily
Study: 27583892
Drug: NOACs (non-vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOACs (non-vitamin K antagonist oral anticoagulants) - appropriate treatment (AT)
Study: 27583892
Drug: NOACs (non-vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOACs (non-vitamin K antagonist oral anticoagulants) - undertreatment (UT)
Study: 27583892
Drug: NOACs (non-vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOACs (non-vitamin K antagonist oral anticoagulants) - overtreatment (OT)
Study: 27586891
Drug: Buspirone 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 20 mg daily for 4 weeks
Study: 27587380
Drug: First salvage
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First salvage treatment
Study: 27587380
Drug: Second salvage
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second salvage treatment
Study: 27587380
Drug: Third or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third or greater salvage treatment
Study: 27588424
Drug: Drisapersen, 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drisapersen, 6 mg/kg subcutaneously, once weekly for 72 weeks, followed by intermittent dosing for 108 weeks (total 188 weeks)
Study: 27589870
Drug: Patient related
Normalized name: Patent Blue
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient related quality of life (measured using EQ-5D-5 L)
Study: 27590145
Drug: CC-930 (JNK
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-930 (JNK inhibitor)
Study: 27595276
Drug: TAPS tool
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAPS tool (interviewer-administered)
Study: 27595276
Drug: TAPS tool
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAPS tool (self-administered)
Study: 27595685
Drug: Monthly benchmarked
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly benchmarked hospital quality reports and recognition of hospital quality achievement.
Study: 27597733
Drug: Propofol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1 mg/kg intravenous bolus, dosing determined by up-and-down method)
Study: 27597740
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept administered at baseline and at 1, 2, and 4 months
Study: 27599452
Drug: Tablet-based training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based training to engage with Personal Health Record (PHR)
Study: 27600044
Drug: Voriconazole administration
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voriconazole administration
Study: 27601554
Drug: AZD1775 as
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1775 as monotherapy (single dose)
Study: 27601554
Drug: AZD1775 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1775 in combination with gemcitabine (1,000 mg/m2)
Study: 27601554
Drug: AZD1775 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1775 in combination with cisplatin or carboplatin
Study: 27602311
Drug: Mesenchymal stromal
Normalized name: Mesenchymal Stromal Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stromal cells (20 million cells implanted once into the nonunion site using a fluoroscopic guide) in combination with platelet lysate (PL) product
Study: 27602967
Drug: 20 mg/ml
Normalized name: urea 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/ml hyaluronic acid filler (Juvéderm Voluma® XC)
Study: 27603290
Drug: Streamlined delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streamlined delivery of antiretroviral therapy (ART) regardless of CD4 cell count, following community-wide HIV-testing.
Study: 27604186
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose sunitinib (20 μM for 6-9 h in vitro; once-weekly in vivo)
Study: 27604186
Drug: Standard daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard daily sunitinib (50 mg daily, four weeks on, two weeks off)
Study: 27604773
Drug: Insulin index
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin index and glycated hemoglobin values
Study: 27604981
Drug: Hydroxycarbamide treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxycarbamide treatment
Study: 27605156
Drug: Bortezomib and
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib and thalidomide therapy
Study: 27607476
Drug: Long-acting opioids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting opioids (morphine and/or hydromorphone)
Study: 27611192
Drug: Plant stanol
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanol enriched margarine (3 g/d plant stanols)